Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002304
- Locations
- 🇺🇸
Eisenhower Med Ctr, Rancho Mirage, California, United States
🇺🇸Univ Hosp, Boston, Massachusetts, United States
🇺🇸Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002075
- Locations
- 🇺🇸
Dr Robert Larsen, Los Angeles, California, United States
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002112
- Locations
- 🇺🇸
California Med Research Group, Fresno, California, United States
🇺🇸UCSF Hosp, San Francisco, California, United States
🇺🇸Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002010
- Locations
- 🇺🇸
HIV Research Group, San Diego, California, United States
🇺🇸Tucson Veterans Administration Med Ctr, Tucson, Arizona, United States
🇺🇸Audie L Murphy Veterans Administration Hosp, San Antonio, Texas, United States
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 300
- Registration Number
- NCT00002446
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
🇺🇸Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States
🇺🇸Miami Veterans Administration Med Ctr, Miami, Florida, United States
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 500
- Registration Number
- NCT00002399
- Locations
- 🇺🇸
Wayne State Univ / Harper Hosp, Detroit, Michigan, United States
🇦🇷Centro de Micologia / Facultad de Medicina UBA, Buenos Aires, Argentina
🇪🇹Faculty of Medicine / Dept of Internal Medicine, Addis Ababa, Ethiopia
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002038
- Locations
- 🇺🇸
Pfizer Central Research, Groton, Connecticut, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002305
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ School of Medicine, Atlanta, Georgia, United States
🇺🇸DeKalb Gen Hosp, Decatur, Georgia, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002277
- Locations
- 🇺🇸
Dr Temple Williams, Houston, Texas, United States
🇺🇸M D Anderson Cancer Ctr, Houston, Texas, United States
🇺🇸Dr Layne Gentry, Houston, Texas, United States
A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002282
- Locations
- 🇺🇸
Dr Robert Larsen, Los Angeles, California, United States
🇺🇸SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇺🇸Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.